XALKORI 250 MG
CRIZOTINIB : 250 MG · DIN 02384264 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is XALKORI?
XALKORI 250 MG contains CRIZOTINIB : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02384264, held by PFIZER CANADA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 10-May-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XALKORI used for?
Monotherapy for ALK-positive or ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02384264 |
|---|---|
| Brand name | XALKORI |
| Generic / active ingredient | CRIZOTINIB : 250 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 250 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01ED01 CRIZOTINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-May-2012 |
| Original market date | 2012-05-10 00:00:00 |
How is it administered?
Recommended dose is 250 mg orally twice daily. Adjustments required for hepatic/renal impairment and toxicities. Capsules must be swallowed whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (section 11 is in TOC but content not in snippet).
How is it supplied?
Bottles of 60 capsules and PVC/aluminum foil blisters containing 60 capsules (6 cards of 10).
Contraindications
Congenital long QT syndrome; persistent QTcF ≥500 msec; known hypersensitivity to crizotinib or any ingredient in the formulation.
Warnings and precautions
QT interval prolongation, bradycardia, hepatotoxicity (including fatal), interstitial lung disease/pneumonitis (including fatal), severe vision loss, and cardiac failure.
What can be used instead?
Other Canadian products sharing ATC code L01ED01 CRIZOTINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| XALKORI | 200 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | DIN 02384256 |
Who else supplies CRIZOTINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CRIZOTINIB appears in 25 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.